Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0524 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Treatment Sequence 1: MK0524 + placebo, MK0524 + montelukast, placebo, placebo, placebo + montelukast |
| 2 | EXPERIMENTAL | Treatment sequence 2: Placebo, montelukast, placebo, MK0524, MK0524 + montelukast |
| Name | Type | Description |
|---|---|---|
| Comparator: MK0524 + placebo | DRUG | Two 150 mg MK0524 tablets + one placebo tablet in the matching image of montelukast 10 mg once daily for 3 weeks |
| Comparator: MK0524 + montelukast | DRUG | Two 150 mg MK0524 tablets and one 10 mg montelukast tablet once daily for 2 weeks |
| Comparator: placebo + montelukast | DRUG | Two placebo tablets in the matching image of MK0524 150 mg and one 10 mg tablet montelukast once daily for 2 weeks |
| Comparator: Placebo | DRUG | During the double-blind treatment periods, patients receive either two placebo tablets in the matching image of MK0524 150 mg or one placebo tablet in the matching image of montelukast 10 mg in a crossover manner. During the washout period before the crossover to the opposite treatment sequence, patients receive two placebo tablets in the matching image of MK0524 150 mg and one placebo tablet in the matching image of montelukast 10 mg once daily for two weeks. |
| MK0524 | DRUG | - |
Inclusion Criteria: * Has symptoms of chronic asthma (shortness of breath, wheezing, chest tightness, etc.) for at least 1 year * Nonsmoker for at least 1 year with a smoking history of no more than 7 pack-years (i.e., 1 pack per day for 7 years) Exclusion Criteria: * Any clinically significant d...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
MK0524 is an investigational small molecule being studied for asthma and seasonal allergies. It has been evaluated in Phase 2 clinical trials in adults with these respiratory and allergic conditions. It is not approved for any indication and remains in clinical development.
MK0524 is being developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker MRK. Merck sponsored the Phase 2 clinical studies of the drug in asthma and seasonal allergic rhinitis.
MK0524 is in Phase 2 clinical development. Both of its reported trials were Phase 2 studies, and both have been completed. The drug is investigational and has not been approved by the FDA for any indication.
MK0524 has been studied in two completed Phase 2 trials. NCT00783601 was an asthma proof-of-concept study with 130 participants, and NCT00533208 was a seasonal allergic rhinitis study with 766 participants. Both enrolled adults and were randomized, double-blind, and controlled.
The MK0524 clinical program enrolled 766 participants in total across its two completed Phase 2 studies. The seasonal allergic rhinitis trial, NCT00533208, accounted for all 766 enrolled participants, while the asthma proof-of-concept trial, NCT00783601, enrolled 130.
Yes, MK0524 is a small molecule therapeutic. It was developed by Merck & Company, Inc. and studied in Phase 2 trials for asthma and seasonal allergies. Both trials have been completed, and no active trials are currently listed for the asset.